BACKGROUND: CD5-positive (CD5 1 ) diffuse large B-cell lymphoma (DLBCL) is characterized by frequent central nervous system recurrence and a predominant activated B-cell-like nature. Primary DLBCL in sanctuary sites (DLBCL-SS) also demonstrates these features, and >70% of patients harbor myeloid differentiation primary response 88 (MYD88) (L265P) and CD79B mutations. The objective of the current study was to elucidate a possible relationship between CD5
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is regarded as a clinicopathologically heterogeneous group of lymphomas and is classified as activated B-cell-like (ABC) DLBCL or germinal center B-cell-like (GCB) DLBCL based on the cell of origin (COO). 1 Nuclear factor-kappa B (NF-jB) activation is indispensable for ABC DLBCL cell survival. Genes in the NF-jB signaling pathway, such as myeloid differentiation primary response 88 (MYD88); CD79A/B; and caspase recruitment domain family member 11 (CARD11), are mutated in ABC DLBCL. 2, 3 MYD88 is an adaptor protein for the Toll/interleukin-1 receptor. The most frequently detected MYD88 mutation is the L265P somatic mutation within the Toll/interleukin-1 receptor domain, 2 which is observed in approximately 30% of patients with ABC DLBCL. 2, 4 This mutation is frequently observed in patients with primary DLBCL in sanctuary sites (DLBCL-SS), such as the central nervous system (CNS) and testis. [5] [6] [7] [8] CD79A and CD79B are proximal B-cell receptor subunits that contain an immunoreceptor tyrosine-based activation motif (ITAM) that frequently harbors somatic mutations.
3 CD79B mutations frequently are detected in the first tyrosine (Y196) of the ITAM. 3, 9 The CD79A ITAM alteration is a splice site mutation and deletion that removes most of the ITAM, and CD79A mutations are rarer than CD79B mutations in patients with ABC DLBCL.
3 CARD11 mutations in patients with DLBCL are reported to be detected exclusively within the coiled-coil domain. 10 CD5 is expressed in approximately 10% of cases of DLBCL. [11] [12] [13] CD5-positive (CD5
1
) DLBCL is characterized by aggressive clinical features and frequent CNS disease recurrence. [14] [15] [16] [17] [18] Chemotherapy with rituximab is reported to have limited efficacy in this disease; the overall survival (OS) rate at 2 years is 70%. 12, 15, [19] [20] [21] Greater than 70% of patients with CD5
1 DLBCL are classified as having ABC DLBCL. [21] [22] [23] To the best of our knowledge, disease-specific molecules have not been identified to date in CD5
1 DLBCL, and no reports have focused on gene mutations related to NF-jB signaling in patients with CD5
1 DLBCL.
To ascertain the frequencies of MYD88 (L265P), CD79A/B, and CARD11 mutations in patients with CD5
1 DLBCL and to determine whether CD5 1 DLBCL demonstrates the same features as DLBCL-SS in terms of gene mutations, we ascertained the mutation status of samples from 40 patients with CD5 1 DLBCL and analyzed the relationship between mutation status and clinical characteristics or prognosis.
MATERIALS AND METHODS

Patients
The current study included 40 patients with CD5 1 DLBCL. All patients were diagnosed with DLBCL, not otherwise specified, according to the 2008 World Health Organization classification 1 between 1993 and 2014 at Mie University Hospital. All specimens were obtained at the time of the initial presentation. CD5 expression in tumor cells was analyzed by immunohistochemistry using frozen sections or by flow cytometry. The COO classification was determined by gene expression profiling (GEP) in 29 patients. 23 In the remaining 11 patients, the COO was identified by immunohistochemistry according to the criteria of Hans et al. 24 Clinical information was obtained from the Mie University Hospital records or supplied by physicians at affiliated hospitals. All patients were treated according to similar protocols at Mie University Hospital or nearby affiliated hospitals. The Institutional Review Board of Mie University approved the current study.
RNA Extraction and Reverse TranscriptasePolymerase Chain Reaction
Total RNA was extracted from frozen tissue samples as described previously. 25 The percentage of tumor cells in the tissue samples was >30% of total cellularity, as determined by immunophenotypic studies (see Supporting Information Table 1 ). Single-strand complementary DNA (cDNA) was synthesized using 5 lg of total RNA, random primers (Invitrogen/Thermo Fisher Scientific, Waltham, Mass), and Ready-To-Go You-Prime FirstStrand Beads (GE Healthcare, Pittsburgh, Pa), as described previously. 26 MYD88 exon 5, the ITAM of CD79A (exons 4-5), the ITAM of CD79B (exons 5-6), and the coiled-coil domain of CARD11 (exons 4-10) were amplified by polymerase chain reaction (PCR) using TaKaRa LA Taq with GC Buffer (Takara Bio Inc, Shiga, Japan). The PCR amplification protocol was as follows: denaturation at 94 8C for 3 minutes followed by 35 cycles of 30 seconds at 94 8C, 30 seconds at 60 8C, and 30 to 40 seconds at 72 8C. Primers for MYD88 were designed to include the L265P mutation site in exon 5. The CD79A and CD79B primers were designed to cover the sequences corresponding to the regions from Y188 to Y199 and from Y196 to Y207, respectively. To amplify CARD11, 2 primer pairs were designed to cover exons 4 to 7 and exons 6 to 10 with an adequate length for direct sequencing. The PCR primer sequences and PCR product sizes are described in Supporting Information Table 2 .
Genomic DNA Extraction and PCR Genomic DNA was extracted from tissue samples from 9 patients whose RNA samples were unavailable. The PCR amplification protocol was the same as that for reverse transcriptase (RT)-PCR, except 28 cycles were included. The PCR primers for MYD88, CD79A, and CD79B are described in Supporting Information Table 2 . CARD11 was examined using only cDNA from RNA samples because the targeted region spanning 7 exons was too long for genomic DNA analysis.
Direct Sequencing
The PCR products were purified using ExoSAP-IT (Affymetrix/USB, Santa Clara, Calif) and the QIAquick PCR Purification Kit (Qiagen, Valencia, CA) and directly sequenced in both directions using the Applied Biosystems 3130xl Genetic Analyzer (Thermo Fisher Scientific Inc). In select cases, including those with wild-type CD79B by Sanger sequencing, the PCR product was cloned using the TOPO TA Cloning Kit (Invitrogen/Thermo Fisher Scientific) according to the manufacturer's protocol. The obtained clones were sent for direct sequencing.
Statistical Analysis
Previously published diagnostic criteria for primary extranodal lymphoma 27 and primary testicular DLBCL 8 were
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Cancer April 1, 2017 used in the current study. Correlations between the 2 groups were examined with the Fisher exact test. Survival data were analyzed using the Kaplan-Meier method. OS was defined as the time from diagnosis until death from any cause or until the date of last follow-up. OS for the 2 groups was compared using the log-rank test. All tests were 2-sided, and a P value < .05 indicated a statistically significant difference. All analyses were performed using IBM SPSS Statistics 23 software (IBM Corporation, Armonk, NY).
RESULTS
Clinical Characteristics
Clinical characteristics at the time of diagnosis for all 40 patients with CD5 1 DLBCL who were analyzed in the current study are shown in Figure 1 and summarized in Table 1 . The median age of the patients was 64 years (range, 15-91 years). Eight patients had primary extranodal lymphoma. Two patients fulfilled the criteria for primary testicular DLBCL. One patient had systemic CD5 1 DLBCL with bone and brain involvement. None of the other patients had CNS involvement at the time of diagnosis.
Mutation Analysis
Direct sequencing was successful with samples from all 40 patients with CD5
1 DLBCL. The mutation analysis results are summarized in Figure 1 . The MYD88 L265P mutation was identified in 13 patients (33%), and no other MYD88 mutations were found. CD79B mutations were detected in 15 patients (38%), and 10 of these patients overlapped with the MYD88-mutated group. Only 1 patient (3%) was found to have a CD79A mutation as well as CD79B and MYD88 mutations. CARD11 was wild-type in all 31 patients examined using cDNA samples. Of the 15 patients with a CD79B mutation, 14 had missense mutations in the ITAM domain; all these mutations occurred in the first tyrosine of the ITAM (Y196H [ Table 2) . One patient had a 13-base deletion in exon 5 before the first tyrosine of the ITAM (see Supporting Information Fig. 1C ). Six of the 10 patients who had both mutations harbored the Y196H mutation in CD79B, whereas only 1 of the 5 patients with a CD79B mutation alone was found to have the Y196H mutation ( Table 2) .
Seven of the 11 patients who did not undergo COO analysis by GEP were characterized as having non-GCB DLBCL by the criteria of Hans et al. 24 Information regarding the COO classification was unavailable for the other 4 patients. Overall, 36 patients had ABC/non-GCB DLBCL (Fig. 1) . The incidence of MYD88 L265P, ‡ , CD5-positive primary testicular lymphoma; † , advanced CD5-positive DLBCL with bone and brain involvement; ABC, activated B-cell-like; CARD11, caspase recruitment domain family member 11; MYD88, myeloid differentiation primary response 88.
CD79B, and CD79A mutations in patients with ABC/ non-GCB DLBCL was 13 of 36 patients (36%), 14 of 36 patients (39%), and 1 of 36 patients (3%), respectively.
Association With Clinical Features and Gene Mutations
Compared with the wild-type MYD88 group, patients in the mutated MYD88 group were characterized by earlystage disease (P 5 .038) and primary extranodal lymphoma (P 5 .008) ( Table 1 ). The presence of the CD79B mutation also was found to be associated with localized disease (P 5 .003). Primary extranodal lymphoma was associated with a higher frequency of both MYD88 and CD79B mutations (P 5 .014).
The clinical features of 18 patients with CD5
1 DLBCL harboring gene mutations are summarized in Table 2 . One of the 2 patients with primary testicular CD5 1 DLBCL had both MYD88 and CD79B (Y196H) mutations. The other patient was found to have only an MYD88 mutation. One patient with advanced CD5 1 DLBCL with bone and brain involvement had both MYD88 and CD79B (Y196H) mutations.
Among the 10 patients with both MYD88 and CD79B mutations, 5 patients had primary extranodal lymphoma. A patient who had soft tissue involvement experienced a CNS recurrence. One of the 3 patients with an MYD88 mutation alone had thyroid involvement. Four of the 5 patients with the CD79B mutation only had at least 1 site of extranodal involvement (Table 2) .
Association Between Survival and Gene Mutation
Clinical information regarding first-line treatment was available for 38 patients. Before 2002, anthracyclinecontaining chemotherapies without rituximab were selected as first-line treatment. Since 2002, the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy with rituximab (R-CHOP) has predominated. For this reason, 18 patients who were treated with R-CHOP were included in the survival 
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Cancer April 1, 2017 analysis in the current study. The COO of these 18 patients was confirmed as ABC/non-GCB DLBCL. Two patients with primary testicular lymphoma and 1 individual with CD5 1 DLBCL with brain involvement were not included in this cohort of 18 patients. With a median follow-up of 7.1 years, there was no significant difference in OS noted based on MYD88 mutation status (P 5 .98) or CD79B mutation status (P 5 .69) (Fig. 2) . Furthermore, there was no significant difference in OS according to MYD88 and CD79B mutation status in the entire CD5 1 DLBCL cohort (data not shown).
The patient with a 13-base deletion in exon 5 had CD5
1 DLBCL with thyroid involvement. This patient experienced a complete response after chemotherapy with R-CHOP and was alive without disease after 9.4 years.
DISCUSSION
The results of the current study demonstrated that the frequencies of MYD88 L265P, CD79B, and CD79A mutations in 40 patients with CD5
1 DLBCL were 33%, 38%, and 3%, respectively. CARD11 was wild-type in all 31 cases examined herein. Patients with CD5
1 DLBCL containing mutated MYD88 and/or CD79B were found to have localized disease more frequently than those with no mutations.
GEP and immunohistochemistry confirmed that 90% of the analyzed CD5
1 DLBCL cases were ABC/ non-GCB DLBCL. The frequencies of MYD88 L265P and CD79A/B mutations in patients with ABC DLBCL were reported to be 29% to 31.2% and 15.6% to 23%, respectively, 2, 4 rates that are comparable to that in patients with CD5
1 DLBCL in the current study (33%). In contrast, the frequency of MYD88 and CD79B double mutations was found to be higher in patients with CD5 1 DLBCL (77% in the MYD88 mutation group) compared with patients with ABC DLBCL in previous reports (33%-36% in the MYD88 mutation group). 2, 9 DLBCL-SS frequently exhibits mutated MYD88. For example, the frequencies of MYD88 mutations in patients with primary CNS lymphoma 5, 6 and vitreoretinal lymphoma 7 were 76% to 94.4% and 69%, respectively. Among patients with primary testicular DLBCL, MYD88 mutations were reported in 94% of primary cases and 80% of secondary cases. 8 The results of the current study indicated that the frequency of MYD88 mutations in patients with CD5
1 DLBCL (33%) was nearly onehalf that of patients with DLBCL-SS. Because the percentage of tumor cells was >30% in all samples examined, it is unlikely that the lower mutation frequency noted in patients with CD5
1 DLBCL was caused by the low sensitivity of Sanger sequencing. The sensitivity and specificity of allele-specific PCR and Sanger sequencing for detecting MYD88 mutations in DLBCL samples are nearly identical when tissue samples with >20% tumor content are analyzed. 28, 29 In addition, primary DLBCL of the CNS is characterized by a high prevalence of CD79B (83%) and MYD88 mutations. 5 Primary testicular DLBCL also frequently harbors CD79B mutations (71%). 30 In the current study, a patient with CNS involvement at the time of diagnosis was found to have both MYD88 and CD79B mutations. Two patients with testicular involvement at the time of diagnosis had MYD88 mutations; 1 of these patients also harbored a CD79B mutation. However, among the other patients with CD5
1 DLBCL, the frequency of MYD88 mutations was 27%, which was lower than that noted among patients with DLBCL-SS. These results indicate that CD5
1 DLBCL is different from DLBCL-SS in terms of gene mutation status and suggest that a small subgroup of patients with CD5 1 DLBCL may harbor similar mutations as patients with DLBCL-SS.
The frequency of CARD11 mutations in patients with ABC DLBCL was reported to be between 6.5% and 8%. 2, 4, 9 No CARD11 mutations were detected in the 31 patients with CD5
1 DLBCL in the current study; this likely is a distinct feature of CD5
1 DLBCL and warrants confirmation in future studies.
MYD88 and CD79B mutations did not appear to affect survival in a multicenter study including 187 patients with DLBCL. 9 In this previous report, 46% of the patients were treated with R-CHOP. A singleinstitutional study including 213 patients with DLBCL who received chemotherapy with R-CHOP demonstrated that MYD88 mutations were associated with a poor outcome in the entire DLBCL cohort, whereas they were not found to be prognostic in the subgroup of patients with ABC DLBCL. 31 In the current study, MYD88 and CD79B mutations did not appear to affect the OS of patients with CD5
1 DLBCL, and a subgroup analysis of patients who received R-CHOP demonstrated similar results. The findings of the current study suggest that MYD88 and CD79B mutations may have no impact on survival in patients with CD5
1 ABC DLBCL who receive chemotherapy with R-CHOP.
It is interesting to note that patients with MYD88-mutated and/or CD79B-mutated CD5
1 DLBCL frequently had localized disease; this is likely a distinct feature of CD5 1 DLBCL because there was no significant difference in stage of disease at the time of presentation reported in previous studies that analyzed all types of DLBCL. 9, 31 It is possible that some pathways common to MYD88 and CD79B are associated with the localization of CD5
1 DLBCL. Moreover, mechanisms distinct from those involved in CD5-negative DLBCL may prevent the dissemination of lymphoma cells in patients with MYD88-mutated and/or CD79B-mutated CD5 1 DLBCL. Despite the high percentage of patients with early-stage disease, the OS of patients with MYD88 and/ or CD79B mutations was not good. These findings suggest a similarity between DLBCL-SS and MYD88-mutated and/or CD79B-mutated CD5 1 DLBCL. In the current study, a previously unreported 13-base deletion in exon 5 was found before the first tyrosine of the ITAM in CD79B in a patient with CD5
1 DLBCL with thyroid involvement who experienced long-term remission after therapy with R-CHOP. To the best of our knowledge, the frequency of CD79B mutations in patients with thyroid DLBCL is unknown. An MYD88 mutation also was found in this patient. No MYD88 mutations were observed in a cohort of 21 patients with thyroid DLBCL. 32 More effective treatment approaches for patients with CD5
1 DLBCL are needed because the OS at 2 years associated with receipt of rituximab-containing chemotherapy is reported to be 70%. 15 MYD88 and CD79B mutations have been associated with tumor response and survival in patients with DLBCL who were treated with lenalidomide or ibrutinib. In a phase 1/2 clinical trial of 80 patients with recurrent or refractory DLBCL who received ibrutinib, CD79B mutations were found to be associated with a good therapeutic response to ibrutinib, whereas MYD88 mutations alone were associated with a poor response. 33 Ibrutinib holds promise for the treatment of the majority of patients with CD5
1 DLBCL because only 8% of the patients in the current study (3 of 40 patients) harbored an MYD88 mutation only.
To the best of our knowledge, the current study is the first to report the frequency of MYD88, CD79B, and CARD11 mutations in what appears to be the largest cohort of patients with CD5
1 DLBCL presented to date. CD5
1 DLBCL is not the same as DLBCL-SS in terms of MYD88 and CD79B mutations, and CARD11 mutations are rare in patients with CD5
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